Community Practice Connections™: Radiation and Medical Oncology Assess Immuno-Oncology Strategies in Stage III NSCLC

Release Date: April 23, 2021
Expiration Date: April 23, 2022

Activity Overview

The management of stage III non–small cell lung cancer (NSCLC) has been altered, with the introduction of immune checkpoint inhibition into the standard of care. This has led to new investigations to determine how best to incorporate immunotherapy into the management of stage III disease.

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from “Radiation and Medical Oncology Assess Immuno-Oncology Strategies in Stage III NSCLC,” broadcast live on April 29. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with stage III NSCLC, putting recent clinical trial data into a clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learnings for those who did.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck & Co., Inc.

Target Audience

This educational program is directed toward the American College of Radiation Oncology (ACRO) audience, primarily radiation oncologists. Medical oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Outline the biological mechanisms underlying the application of immune checkpoint inhibitors in the context of radiotherapy in the treatment of stage III NSCLC
• Evaluate recently reported clinical trials that have evaluated the role of immune checkpoint inhibitors in the treatment of stage III NSCLC
• Apply recent evidence regarding efficacy and adverse event (AE) profiles of immune checkpoint inhibitors and chemoradiotherapy to real-world clinical scenarios typically encountered in the management of stage III NSCLC
• Identify strategies to improve multidisciplinary communication and the coordination of care between radiation and medical oncologists in the treatment of NSCLC

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Faculty

Roy H. Decker, MD, PhD
Professor and Vice Chair
Department of Therapeutic Radiology
Associate Cancer Center Director for Clinical Sciences
Yale School of Medicine
New Haven, CT

Disclosures: Speakers’ Bureau: AstraZeneca.

Sarah B. Goldberg, MD, MPH
Associate Professor of Internal Medicine (Medical Oncology)
Yale School of Medicine
Yale Cancer Center
New Haven, CT

Disclosures: Grant/Research Support: AstraZeneca, Boehringer Ingelheim; Consultant: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Genentech, Regeneron, Sanofi Genzyme.

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine (Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Cancer Center Director, Translational Science
Yale Cancer Center and Smilow Cancer Hospital
New Haven, CT

Disclosures: Grant/Research Support: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck & Co; Consultant: AbbVie Pharmaceuticals, ARMO BioSciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Cybrexa Therapeutics, eFFECTOR Therapeutics, Inc, Eli Lilly and Company, EMD Serono, Genentech/Roche, Genmab, Halozyme Therapeutics, Heat Biologics, I-Mab Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck & Co, Mirati Therapeutics, Nektar Therapeutics, Neon Therapeutics, NextCure, Novartis, Oncternal Therapeutics, Pfizer, Ribon Therapeutics, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, STCube Pharmaceuticals, Inc, Symphogen, Takeda, Tesaro, Tocagen, WindMIL Therapeutics, Xencor, Inc; Other: Immunocore Holdings Limited (Board of Directors), Junshi Pharmaceuticals (Board of Directors).

Salma Jabbour, MD
Professor
Vice Chair of Clinical Research & Faculty Development
Clinical Chief, Radiation Oncology at RWJUH/Rutgers Cancer Institute
Department of Radiation Oncology
Rutgers Cancer Institute of New Jersey
Robert Wood Johnson Medical School
Rutgers University
New Brunswick, NJ

Disclosures: Grant/Research Support: Merck & Co; Consultant: IMX Medical, Merck & Co, Syntactx.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.